Новая коронавирусная инфекция COVID-19 как триггер развития симптомов анкилозирующего спондилита. Клиническое наблюдение
________________________________________________
Rumiantceva DG, Urumova MM, Erdes ShF. New coronavirus infection COVID-19 as a trigger for the development of symptoms of ankylosing spondylitis. Case report. Terapevticheskii Arkhiv (Ter. Arkh.). 2021; 93 (5): 609–612.
DOI: 10.26442/00403660.2021.05.200793
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Ключевые слова: анкилозирующий спондилит, новая коронавирусная инфекция COVID-19, SARS-CoV-2
________________________________________________
The novel coronavirus infection COVID-19 (SARS-CoV-2) is now known to cause a variety of extrapulmonary complications, including cardiovascular, neurological and dermatological complications, many of which occur or last several weeks after infection. We present a clinical case of a patient who first developed symptoms of ankylosing spondylitis 2 weeks after recovering from COVID-19. The patient was prescribed therapy in accordance with international and Russian recommendations for the management of patients with ankylosing spondylitis with a positive effect in the form of absence arthritis, enthesitis and reducing the inflammatory back pain.
Keywords: ankylosing spondylitis, spondyloarthritis, novel coronavirus infection COVID-19, SARS-CoV-2
2. WHO Coronavirus (COVID-19) Dashboard. Available: https://covid19.who.int. Accessed: 05.05.2021.
3. Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol. 2020;92(6):568-76. DOI:10.1002/jmv.25748
4. Guan WJ, Zhong NS. Clinical characteristics of Covid-19 in China. N Engl J Med. 2020;382(19):1861–2. DOI:10.1056/nejmc2005203
5. Yang W, Cao Q, Qin L, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):a multi-center study in Wenzhou city, Zhejiang, China. J Infect. 2020;80:388-93. DOI:10.1016/j.jinf.2020.02.016
6. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507-13. DOI:10.1016/s0140-6736(20)30211-7
7. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-Infected pneumonia in Wuhan, China. JAMA. 2020;323:1061-9. DOI:10.1001/jama.2020.1585
8. Xie HT, Jiang SY, Xu KK, et al. SARS-CoV-2 in the ocular surface of COVID-19 patients. Eye Vis (Lond). 2020;7:23.DOI:10.1186/s40662-020-00189-0
9. Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):1-9. DOI:10.1001/jamaneurol.2020.1127
10. Wang L, Wang Y, Ye D, et al. Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence. Int J Antimicrob Agents. 2020;55:105948. DOI:10.1016/j.ijantimicag.2020.105948
11. Ono K, Kishimoto M, Shimasaki T, et al. Reactive arthritis after COVID-19 infection. RMD Open. 2020;6:e001350.DOI:10.1136/rmdopen-2020-001350
12. Эрдес Ш.Ф., Бадокин В.В., Бочкова А.Г., и др. О терминологии спондилоартритов. Научно-практическая ревматология. 2015;53(6):657-60 [Erdes SF, Badokin VV, Bochkova AG, et al. On the terminology of spondyloarthritis. Rheumatology Science and Practice. 2015;53(6):657‑60 (in Russian)]. DOI:10.14412/1995-4484-2015-657-660
13. Wan S, Yi Q, Fan S, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). medRxiv. 2020.DOI:10.1101/2020.02.10.20021832
14. Насонов Е.Л. Иммунопатология и иммунофармакотерапия коронавирусной болезни 2019 (COVID-19): фокус на интерлейкин 6. Научно-
практическая ревматология. 2020;58(3):245-61 [Nasonov EL. Immunopathology and immunopharmacotherapy of coronavirus disease 2019 (COVID-19): focus on interleukin 6. Rheumatology Science and Practice. 2020;58(3):245-61 (in Russian)]. DOI:10.14412/1995-4484-2020-245-261
15. Liu Y, Zhang C, Huang F, et al. Elevated plasma level of selective cytokines in COVID-19 patients reflect viral load and lung injury. Nat Sci Rev. 2020:nwaa037. DOI:10.1093/nsr/nwaa037
16. Liu J, Li S, Liu J, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763.DOI:10.1016/j.ebiom.2020.102763
________________________________________________
1. Wang H, Li X, Li T, et al. The genetic sequence, origin, and diagnosis of SARS-CoV-2. Eur J Clin Microbiol Infect Dis. 2020;39(9):1629-35. DOI:10.1007/s10096-020-03899-4
2. WHO Coronavirus (COVID-19) Dashboard. Available: https://covid19.who.int. Accessed: 05.05.2021.
3. Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol. 2020;92(6):568-76. DOI:10.1002/jmv.25748
4. Guan WJ, Zhong NS. Clinical characteristics of Covid-19 in China. N Engl J Med. 2020;382(19):1861–2. DOI:10.1056/nejmc2005203
5. Yang W, Cao Q, Qin L, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):a multi-center study in Wenzhou city, Zhejiang, China. J Infect. 2020;80:388-93. DOI:10.1016/j.jinf.2020.02.016
6. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507-13. DOI:10.1016/s0140-6736(20)30211-7
7. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-Infected pneumonia in Wuhan, China. JAMA. 2020;323:1061-9. DOI:10.1001/jama.2020.1585
8. Xie HT, Jiang SY, Xu KK, et al. SARS-CoV-2 in the ocular surface of COVID-19 patients. Eye Vis (Lond). 2020;7:23.DOI:10.1186/s40662-020-00189-0
9. Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):1-9. DOI:10.1001/jamaneurol.2020.1127
10. Wang L, Wang Y, Ye D, et al. Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence. Int J Antimicrob Agents. 2020;55:105948. DOI:10.1016/j.ijantimicag.2020.105948
11. Ono K, Kishimoto M, Shimasaki T, et al. Reactive arthritis after COVID-19 infection. RMD Open. 2020;6:e001350.DOI:10.1136/rmdopen-2020-001350
12. Erdes SF, Badokin VV, Bochkova AG, et al. On the terminology of spondyloarthritis. Rheumatology Science and Practice. 2015;53(6):657‑60 (in Russian)
DOI:10.14412/1995-4484-2015-657-660
13. Wan S, Yi Q, Fan S, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). medRxiv. 2020.DOI:10.1101/2020.02.10.20021832
14. Nasonov EL. Immunopathology and immunopharmacotherapy of coronavirus disease 2019 (COVID-19): focus on interleukin 6. Rheumatology Science and Practice. 2020;58(3):245-61 (in Russian) DOI:10.14412/1995-4484-2020-245-261
15. Liu Y, Zhang C, Huang F, et al. Elevated plasma level of selective cytokines in COVID-19 patients reflect viral load and lung injury. Nat Sci Rev. 2020:nwaa037. DOI:10.1093/nsr/nwaa037
16. Liu J, Li S, Liu J, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763.DOI:10.1016/j.ebiom.2020.102763
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», Москва, Россия
*rumiantceva01@gmail.com
________________________________________________
Daria G. Rumiantceva*, Margarita M. Urumova, Shandor F. Erdes
Nasonova Research Institute of Rheumatology, Moscow, Russia
*rumiantceva01@gmail.com